(This Nov. 22 story has been corrected to fix the list price of Pfizer's drug to about $268,000, not $225,000, in paragraph 3 ...
BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted ...
GET MORE AI-GENERATED SIGNALS: December 02, 2024, 04:48 am ET, BY Jesse F.- Contributor| Editor: Thomas H. Kee Jr. ( Follow ...
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price upped by HC Wainwright from $43.00 to $49.00 in a research ...
We project BridgeBio's key drug candidate, Attruby (acoramidis), could achieve global sales of around $3.3 billion by 2033. Attruby is an oral drug designed to treat transthyretin amyloid ...
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price increased by Bank of America from $42.00 to $45.00 in a ...
California-based BridgeBio has secured US FDA approval for its lead candidate drug, acoramidis (brand name Attruby) for ...
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...
PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to ...
On Friday, BridgeBio Pharma Inc (BBIO) stock saw a decline, ending the day at $27.33 which represents a decrease of $-0.16 or -0.58% from the prior close of $27.49. The stock opened at $27.84 and ...
BridgeBio Pharma, Inc. BBIO recently announced that it obtained FDA approval for its pipeline candidate acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy (ATTR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback